Am I eligible?

You may be eligible if you are:

  • A resident of the United States
  • A pregnant woman diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis who has:
    • Used SKYRIZI® (risankizumab-rzaa) during pregnancy or just prior to pregnancy (within 20 weeks prior to conception)
    • Used other similar medications for these conditions during pregnancy or just prior to pregnancy*

*Please note: If you have used other medications similar to risankizumab, such as TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, JAK inhibitors and or integrin receptor antagonists, you may be eligible to participate. These medications include Stelara (ustekinumab), Cosentyx (secukinumab), Siliq (brodalumab), Taltz (ixekizumab), Tremfya (guselkumab), Ilumya (tildrakizumab), Enbrel (etanercept) or biosimilar (Erelzi, Eticovo, etc), Remicade (infliximab) or biosimilar (Avsola, Inflectra, Ixifi, Renflexis, etc), Humira (adalimumab) or biosimilar (Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, etc), Cimzia (certolizumab), Simponi (golimumab), ORENCIA (abatacept), ENTYVIO (vedolizumab), Rinvoq (upadacitinib), Tysarbri (natalizumab), Omvoh (mirikizumab), BIMZELX (bimekizumab), or Xeljanz (tofacitinib). If you have used any of these medications during or just prior to pregnancy, the registry staff can help determine your eligibility.

Third-party trademarks used herein are trademarks of their respective owners.

Contact request form

Complete this form and a registry team member will contact you with more information about participating in the Registry.

* marks required field.

I authorize the GLOW Pregnancy Registry to contact me and/or leave a message for me at these numbers or to contact me via email at the address listed below. I agree to the Registry referencing the GLOW Pregnancy Registry in messages or emails.

The registry is open from 8.30 am – 5.00 pm ET Monday-Friday

Please identify the best time of day for contact.

Please identify the best day for contact.

Privacy Statement:

PPD respects your privacy. The information you provide will be used, based on your consent, to contact you and assess your eligibility for the GLOW Pregnancy Registry. AbbVie, Inc. is responsible for your personal data, and PPD acts on its behalf and will keep your information secure. Your identifiable information will not be shared by PPD with the sponsor or any third party without your permission. If you choose not to enroll, we may ask for your consent to share your contact details with the sponsor for safety follow-up; if you do not provide permission, your details will be deleted. You may withdraw your consent at any time and may have rights to access, correct, or delete your data, depending on your location. Your data will be kept only as long as necessary for these purposes. You may also have the right to contact your local data protection or privacy authority. For more information, please see the AbbVie Privacy Notice.